Stem Cells in Toxicology and Medicine – Biotechnology, Healthcare, Stem Cells Industries

The Stem Cells in Toxicology and Medicine Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

A comprehensive and authoritative compilation of up–to–date developments in stem cell research and its use in toxicology and medicine

  • Presented by internationally recognized investigators in this exciting field of scientific research
  • Provides an insight into the current trends and future directions of research in this rapidly developing new field
  • A valuable and excellent source of authoritative and up–to–date information for researchers, toxicologists, drug industry, risk assessors and regulators in academia, industry and government

Read more and order at Stem Cells in Toxicology and Medicine

Commercializing the Stem Cell Sciences. Woodhead Publishing Series in Biomedicine – Biotechnology, Healthcare, Stem Cells Industries

The Commercializing the Stem Cell Sciences. Woodhead Publishing Series in Biomedicine Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

Promising new developments in biomedical technology such as stem cell science are widely endorsed by governments keen to reduce spiralling healthcare costs, clinicians focused on patient care, and patients demanding revolutionary new treatments. Commercializing the stem cell sciences offers a comparative analysis of the commercial methods adopted in the global stem cell industries. It seeks to establish whether there is an optimum commercial model and to examine what emerging companies can learn from their predecessors. Following an introduction to stem cell sciences and the problems involved in their commercialization, the book begins with a discussion of stem cell treatments from a global perspective, and the role of innovation in the commercialization of biotechnology in general. In the second half of the book, chapters focus on the different strategies that can be employed and their relative risks and values, before a conclusion that looks at potential new developments in the field.

  • In-depth discussion of case studies of products undergoing development
  • Focus on commercial optimization of stem cell treatments
  • Analysis in a global context and covering a diverse range of countries

Read more and order at Commercializing the Stem Cell Sciences. Woodhead Publishing Series in Biomedicine

Global and Chinese Embryonic Stem Cell (hESC) Products Industry – 2016 – Biotechnology, Healthcare, Stem Cells Industries

The Global and Chinese Embryonic Stem Cell (hESC) Products Industry – 2016 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

The 'Global and Chinese Embryonic Stem Cell (hESC) Products Industry – 2016' report is a professional and in-depth study on the current state of the global Embryonic Stem Cell (hESC) Products industry with a focus on the Chinese market. The report provides key statistics on the market status of the Embryonic Stem Cell (hESC) Products manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2011-2016 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of Embryonic Stem Cell (hESC) Products industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2016-2021 market development trends of Embryonic Stem Cell (hESC) Products industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

In the end, the report makes some important proposals for a new project of Embryonic Stem Cell (hESC) Products Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Embryonic Stem Cell (hESC) Products industry covering all important parameters.

PLEASE NOTE: This report will be completed after order and will take approximately 2-3 business days after the confirmation of payment.

Read more and order at Global and Chinese Embryonic Stem Cell (hESC) Products Industry – 2016

Funded Research in Stem Cell Research – Biotechnology, Healthcare, Stem Cells Industries

The Funded Research in Stem Cell Research Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

Follow the Grants Money – A Comprehensive Guide to Research Funding from OpenGrants

The team at OpenGrants is providing a "first of a kind" grants dataset.

This report will provide global transparency to research funded for Stem Cell Research – based on models of NIH definitions for those topic areas.

Using these models, we will provide you with 5 years of Stem Cell Research Grant Funding data from the top global funders of Science Research – representing over 80 different funding organizations worldwide.

Which global funders are providing the most resources in Stem Cell Research?
Which institutions are receiving the most awards?
Which investigators are leading the field in new and current funding/projects?
What funds have been targeted in this field for future years (projects won in 2013, 2014 which will fund for the next 2-3 years)

This is the most forward-looking and current research data source on Stem Cell Research.

Funding includes 5 years of data from the major science and biomedical funders in Europe, North America, and Australia.

Database Sources Include, but are not limited to:

European Commission (EC)
European Research Council (ERC)
Australian Research Council (ARC)
National Health and Medical Research Council (NHMRC)
Austrian Science Fund (FWF)
Canadian Institutes of Health Research (CIHR)
Natural Sciences and Engineering Research Council of Canada (NSERC)
Fondazione Telethon (Fondazione Telethon)
Fundação para a Ciência e a Tecnologia, I.P. (FCT)
Action on Hearing Loss (Action on Hearing Loss)
Arthritis Research UK (Arthritis Research UK)
Arts and Humanities Research Council (AHRC)
Biotechnology and Biological Sciences Research Council (BBSRC)
Breakthrough Breast Cancer (Breakthrough Breast Cancer)
British Heart Foundation (BHF)
Cancer Research UK (CR-UK)
Chief Scientist Office (CSO)
Diabetes UK (Diabetes UK)
Dunhill Medical Trust (DMT)
Economic and Social Research Council (ESRC)
Engineering and Physical Sciences Research Council (EPSRC)
Medical Research Council (MRC)
Motor Neurone Disease Association (MNDA )
Multiple Sclerosis Society (MS Society)
Myrovlytis Trust (Myrovlytis Trust)
National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
National Institute for Health Research (NIHR unassigned)
Natural Environment Research Council (NERC)
NIHR Central Commissioning Facility (NIHR CCF)
NIHR Evaluation, Trials and Studies Coordinating Centre (NIHR NETSCC)
NIHR Trainees Coordinating Centre (NIHR TCC)
Parkinson's UK (Parkinson's UK)
Prostate Cancer UK (Prostate Cancer UK)
Science and Technology Facilities Council (STFC)
Technology Strategy Board (TSB)
Wellcome Trust (WT)
Worldwide Cancer Research (WCR)
Yorkshire Cancer Research (YCR)
Administration for Children and Families (ACF)
Agency for Healthcare Research and Quality (AHRQ)
Agricultural Research Service (ARS)
Bladder Cancer Advocacy Network (BCAN)
Center for Neuroscience and Regenerative Medicine (CNRM)
Centers for Disease Control and Prevention (CDC)
Congressionally Directed Medical Research Programs (CDMRP)
Environmental Protection Agency (EPA)
Fogarty International Center (FIC)
Health Resources and Services Administration (HRSA)
National Aeronautics and Space Administration (NASA)
National Cancer Institute (NCI)
National Center for Advancing Translational Sciences (NCATS)
National Center for Complementary and Alternative Medicine (NCCAM)
National Center for Research Resources (NCRR)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute (NHLBI)
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Child Health and Human Development (NICHD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Food and Agriculture (NIFA)
National Institute of General Medical Sciences (NIGMS)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Nursing Research (NINR)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute on Drug Abuse (NIDA)
National Institute on Minority Health and Health Disparities (NIMHD)
National Library of Medicine (NLM)
National Science Foundation (NSF)
NIH Office of the Director (OD)
Substance Abuse and Mental Health Services Administration (SAMHSA)
U.S. Department of Veterans Affairs (VA)
U.S. Food and Drug Administration (FDA)
US Forestry Service (USFS)

Read more and order at Funded Research in Stem Cell Research

Regenerative Medicine and Stem Cell Based Cell therapies-Drugs of the Future Offering Hope for Cure – Biotechnology, Healthcare, Stem Cells Industries

The Regenerative Medicine and Stem Cell Based Cell therapies-Drugs of the Future Offering Hope for Cure Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the life expectancy WW. However, this has not translated into any reduction in the incidence or prevalence of chronic or critical illnesses! On the contrary the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected to

achieve sales in excess of trillion dollar mark by 2020 By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a close watch for those interested in keeping pace with the development of new medicines.

The report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. The therapy class report highlights the future potential of this stream of medicine and the radical way diseases could be treated in the next few decades. This new stream of medicine is driven by landmark scientific discoveries and research (Nobel prize in 2012).

Read more and order at Regenerative Medicine and Stem Cell Based Cell therapies-Drugs of the Future Offering Hope for Cure

The 2018-2023 World Outlook for Umbilical Cord Blood Stem Cells – Biotechnology, Healthcare, Stem Cells Industries

The The 2018-2023 World Outlook for Umbilical Cord Blood Stem Cells Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

This study covers the world outlook for umbilical cord blood stem cells across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for umbilical cord blood stem cells. It also shows how the P.I.E. is divided across the world's regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

1.3 The Methodology

In order to estimate the latent demand for umbilical cord blood stem cells on a worldwide basis, I used a multi-stage approach. Before applying the approach, one needs a basic theory from which such estimates are created. In this case, I heavily rely on the use of certain basic economic assumptions. In particular, there is an assumption governing the shape and type of aggregate latent demand functions. Latent demand functions relate the income of a country, city, state, household, or individual to realized consumption. Latent demand (often realized as consumption when an industry is efficient), at any level of the value chain, takes place if an equilibrium is realized. For firms to serve a market, they must perceive a latent demand and be able to serve that demand at a minimal return. The single most important variable determining consumption, assuming latent demand exists, is income (or other financial resources at higher levels of the value chain). Other factors that can pivot or shape demand curves include external or exogenous shocks (i.e., business cycles), and or changes in utility for the product in question.

Ignoring, for the moment, exogenous shocks and variations in utility across countries, the aggregate relation between income and consumption has been a central theme in economics. The figure below concisely summarizes one aspect of problem. In the 1930s, John Meynard Keynes conjectured that as incomes rise, the average propensity to consume would fall. The average propensity to consume is the level of consumption divided by the level of income, or the slope of the line from the origin to the consumption function. He estimated this relationship empirically and found it to be true in the short-run (mostly based on cross-sectional data). The higher the income, the lower the average propensity to consume. This type of consumption function is shown as "B" in the figure below (note the rather flat slope of the curve). In the 1940s, another macroeconomist, Simon Kuznets, estimated long-run consumption functions which indicated that the marginal propensity to consume was rather constant (using time series data across countries). This type of consumption function is show as "B" in the figure below (note the higher slope and zero-zero intercept).

The average propensity to consume is constant. For a general overview of this subject area, see Principles of Macroeconomics by N. Gregory Mankiw, South-Western College Publishing; ISBN: 0030340594; 2nd edition (February 2002).

Is it declining or is it constant? A number of other economists, notably Franco Modigliani and Milton Friedman, in the 1950s (and Irving Fisher earlier), explained why the two functions were different using various assumptions on intertemporal budget constraints, savings, and wealth. The shorter the time horizon, the more consumption can depend on wealth (earned in previous years) and business cycles. In the long-run, however, the propensity to consume is more constant. Similarly, in the long-run, households, industries, or countries with no income eventually have no consumption (wealth is depleted). While the debate surrounding beliefs about how income and consumption are related and interesting, in this study a very particular school of thought is adopted. In particular, we are considering the latent demand for umbilical cord blood stem cells across some 190 countries. The smallest have fewer than 10,000 inhabitants. I assume that all of these counties fall along a "long-run" aggregate consumption function. This long-run function applies despite some of these countries having wealth; current income dominates the latent demand for umbilical cord blood stem cells. So, latent demand in the long-run has a zero intercept. However, I allow firms to have different propensities to consume (including being on consumption functions with differing slopes, which can account for differences in industrial organization, and end-user preferences).

Given this overriding philosophy, I will now describe the methodology used to create the latent demand estimates for umbilical cord blood stem cells. Since this methodology applies to a large number of categories, the rather academic discussion below is general and can be applied to a wide variety of categories, not just umbilical cord blood stem cells.

1.3.1 Step 1. Product Definition And Data Collection

Any study of latent demand across countries requires that some standard be established to define "efficiently served". Having implemented various alternatives and matched these with market outcomes, I have found that the optimal approach is to assume that certain key countries are more likely to be at or near efficiency than others. These countries are given greater weight than others in the estimation of latent demand compared to other countries for which no known data are available. Of the many alternatives, I have found the assumption that the world’s highest aggregate income and highest income-per-capita markets reflect the best standards for “efficiency”. High aggregate income alone is not sufficient (i.e., China has high aggregate income, but low income per capita and cannot be assumed to be efficient). Aggregate income can be operationalized in a number of ways, including gross domestic product (for industrial categories), or total disposable income (for household categories; population times average income per capita, or number of households times average household income per capita). Brunei, Nauru, Kuwait, and Lichtenstein are examples of countries with high income per capita, but not assumed to be efficient, given low aggregate level of income (or gross domestic product); these countries have, however, high incomes per capita but may not benefit from the efficiencies derived from economies of scale associated with large economies. Only countries with high income per capita and large aggregate income are assumed efficient. This greatly restricts the pool of countries to those in the OECD (Organization for Economic Cooperation and Development), like the United States, or the United Kingdom (which were earlier than other large OECD economies to liberalize their markets).

The selection of countries is further reduced by the fact that not all countries in the OECD report have industry revenues at the category level. Countries that typically have ample data at the aggregate level that meet the efficiency criteria include the United States, the United Kingdom, and in some cases France and Germany.
Is it declining or is it constant? A number of other economists, notably Franco Modigliani and Milton Friedman, in the 1950s (and Irving Fisher earlier), explained why the two functions were different using various assumptions on intertemporal budget constraints, savings, and wealth. The shorter the time horizon, the more consumption can depend on wealth (earned in previous years) and business cycles. In the long-run, however, the propensity to consume is more constant. Similarly, in the long-run, households, industries, or countries with no income eventually have no consumption (wealth is depleted). While the debate surrounding beliefs about how income and consumption are related and interesting, in this study a very particular school of thought is adopted. In particular, we are considering the latent demand for umbilical cord blood stem cells across some 190 countries. The smallest have fewer than 10,000 inhabitants. I assume that all of these counties fall along a "long-run" aggregate consumption function. This long-run function applies despite some of these countries having wealth; current income dominates the latent demand for umbilical cord blood stem cells. So, latent demand in the long-run has a zero intercept. However, I allow firms to have different propensities to consume (including being on consumption functions with differing slopes, which can account for differences in industrial organization, and end-user preferences).Given this overriding philosophy, I will now describe the methodology used to create the latent demand estimates for umbilical cord blood stem cells. Since this methodology applies to a large number of categories, the rather academic discussion below is general and can be applied to a wide variety of categories, not just umbilical cord blood stem cells.

1.3.1 Step 1. Product Definition And Data Collection

Any study of latent demand across countries requires that some standard be established to define "efficiently served". Having implemented various alternatives and matched these with market outcomes, I have found that the optimal approach is to assume that certain key countries are more likely to be at or near efficiency than others. These countries are given greater weight than others in the estimation of latent demand compared to other countries for which no known data are available. Of the many alternatives, I have found the assumption that the world’s highest aggregate income and highest income-per-capita markets reflect the best standards for “efficiency”. High aggregate income alone is not sufficient (i.e., China has high aggregate income, but low income per capita and cannot be assumed to be efficient). Aggregate income can be operationalized in a number of ways, including gross domestic product (for industrial categories), or total disposable income (for household categories; population times average income per capita, or number of households times average household income per capita). Brunei, Nauru, Kuwait, and Lichtenstein are examples of countries with high income per capita, but not assumed to be efficient, given low aggregate level of income (or gross domestic product); these countries have, however, high incomes per capita but may not benefit from the efficiencies derived from economies of scale associated with large economies. Only countries with high income per capita and large aggregate income are assumed efficient. This greatly restricts the pool of countries to those in the OECD (Organization for Economic Cooperation and Development), like the United States, or the United Kingdom (which were earlier than other large OECD economies to liberalize their markets).The selection of countries is further reduced by the fact that not all countries in the OECD report have industry revenues at the category level. Countries that typically have ample data at the aggregate level that meet the efficiency criteria include the United States, the United Kingdom, and in some cases France and Germany.Latent demand is therefore estimated using data collected for relatively efficient markets from independent data sources (e.g. Euromonitor, Mintel, Thomson Financial Services, the U.S. Industrial Outlook, the World Resources Institute, the Organization for Economic Cooperation and Development, various agencies from the United Nations, industry trade associations, the International Monetary Fund, and the World Bank). Depending on original data sources used, the definition of "umbilical cord blood stem cells" is established. In the case of this report, the data were reported at the aggregate level, with no further breakdown or definition. In other words, any potential products that might be incorporated within umbilical cord blood stem cells fall under this category. Public sources rarely report data at the disaggregated level in order to protect private information from individual firms that might dominate a specific product-market. These sources will therefore aggregate across components of a category and report only the aggregate to the public. While private data are certainly available, this report only relies on public data at the aggregate level without reliance on the summation of various category components. In other words, this report does not aggregate a number of components to arrive at the "whole". Rather, it starts with the "whole", and estimates the whole for all countries and the world at large (without needing to know the specific parts that went into the whole in the first place).Given this caveat, in this report we define the sales of umbilical cord blood stem cells as including all commonly understood products falling within this broad category, such as stem cell transplants, autologous transplants, and allogeneic transplants, regenerative medicines, and cord blood banking, blood transfusion, and cell based genetics technologies, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics, and Athersys. In addition to the sources indicated below, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication’s release in 2017).This report was prepared from a variety of sources including excerpts from documents and official reports or databases published by the World Bank, the U.S. Department of Commerce, the U.S. State Department, various national agencies, the International Monetary Fund, the Central Intelligence Agency, various agencies from the United Nations (e.g. ILO, ITU, UNDP, etc.), and non-governmental sources and various public sources cited in the trade press.

1.3.2 Step 2. Filtering And Smoothing

Based on the aggregate view of umbilical cord blood stem cells as defined above, data were then collected for as many similar countries as possible for that same definition, at the same level of the value chain. This generates a convenience sample of countries from which comparable figures are available. If the series in question do not reflect the same accounting period, then adjustments are made. In order to eliminate short-term effects of business cycles, the series are smoothed using a 2-year moving average weighting scheme (longer weighting schemes do not substantially change the results). If data are available for a country, but these reflect short-run aberrations due to exogenous shocks (such as would be the case of beef sales in a country stricken with foot and mouth disease), these observations were dropped or "filtered" from the analysis.

1.3.3 Step 3. Filling In Missing Values

In some cases, data are available for countries on a sporadic basis. In other cases, data from a country may be available for only one year. From a Bayesian perspective, these observations should be given the greatest weight in estimating missing years. Assuming that other factors are held constant, the missing years are extrapolated using changes and growth in aggregate national income. Based on the overriding philosophy of a long-run consumption function (defined earlier), countries which have missing data for any given year are estimated based on historical dynamics of aggregate income for that country.

1.3.4 Step 4. Varying Parameter, Non-Linear Estimation

Given the data available from the first three steps, the latent demand in additional countries is estimated using a "varying-parameter cross-sectionally pooled time series model".

The interested reader can find longer discussions of this type of modeling in Studies in Global Econometrics (Advanced Studies in Theoretical and Applied Econometrics V. 30), by Henri Theil, et al., Kluwer Academic Publishers; ISBN: 0792336607; (June 1996), and in Principles of Econometrics, by Henri Theil John Wiley & Sons; ISBN: 0471858455; (December 1971), and in Econometric Models and Economic Forecasts by Robert S. Pindyck, Daniel L. Rubinfeld McGraw Hill Text; ISBN: 0070500983; 3rd edition (December 1991). Simply stated, the effect of income on latent demand is assumed to be constant across countries unless there is empirical evidence to suggest that this effect varies (i.e., the slope of the income effect is not necessarily the same for all countries). This assumption applies across countries along the aggregate consumption function, but also over time (i.e., not all countries are perceived to have the same income growth prospects over time and this effect can vary from country to country as well). Another way of looking at this is to say that latent demand for umbilical cord blood stem cells is more likely to be similar across countries that have similar characteristics in terms of economic development (i.e., African countries will have similar latent demand structures controlling for the income variation across the pool of African countries). This approach is useful across countries for which some notion of non-linearity exists in the aggregate cross-country consumption function. For some categories, however, the reader must realize that the numbers will reflect a country’s contribution to global latent demand and may never be realized in the form of local sales. For certain country-category combinations this will result in what at first glance will be odd results. For example, the latent demand for the category "space vehicles" will exist for Togo even though they have no space program. The assumption is that if the economies in these countries did not exist, the world aggregate for these categories would be lower. The share attributed to these countries is based on a proportion of their income (however small) being used to consume the category in question (i.e., perhaps via resellers).

1.3.5 Step 5. Fixed-Parameter Linear Estimation

Nonlinearities are assumed in cases where filtered data exist along the aggregate consumption function. Because the world consists of more than 200 countries, there will always be those countries, especially toward the bottom of the consumption function, where non-linear estimation is simply not possible. For these countries, equilibrium latent demand is assumed to be perfectly parametric and not a function of wealth (i.e., a country’s stock of income), but a function of current income (a country’s flow of income). In the long run, if a country has no current income, the latent demand for umbilical cord blood stem cells is assumed to approach zero. The assumption is that wealth stocks fall rapidly to zero if flow income falls to zero (i.e., countries which earn low levels of income will not use their savings, in the long run, to demand umbilical cord blood stem cells). In a graphical sense, for low-income countries, latent demand approaches zero in a parametric linear fashion with a zero-zero intercept. In this stage of the estimation procedure, low-income countries are assumed to have a latent demand proportional to their income, based on the country closest to it on the aggregate consumption function.

1.3.6 Step 6. Aggregation And Benchmarking

Based on the models described in Chapter 1, latent demand figures are estimated for all countries of the world, including for the smallest economies. These are then aggregated to get world totals and regional totals. To make the numbers more meaningful, regional and global demand averages are presented. Figures are rounded, so minor inconsistencies may exist across tables.

1.3.7 Step 7. Latent Demand Density: Allocating Across Cities

With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report also covers the world’s top 2,000 cities. The purpose is to understand the density of demand within a country and the extent to which a city might be used as a point of distribution within its region. From an economic perspective, however, a city does not represent a population within rigid geographical boundaries. To an economist or strategic planner, a city represents an area of dominant influence over markets in adjacent areas. This influence varies from one industry to another, but also from one period of time to another.

Similar to country-level data, the reader needs to realize that latent demand allocated to a city may or may not represent real sales. For many items, latent demand is clearly observable in sales, as in the case for food or housing items. Consider, again, the category "satellite launch vehicles." Clearly, there are no launch pads in most cities of the world. However, the core benefit of the vehicles (e.g. telecommunications, etc.) is "consumed" by residents or industries within the world's cities. Without certain cities, in other words, the world market for satellite launch vehicles would be lower for the world in general. One needs to allocate, therefore, a portion of the worldwide economic demand for launch vehicles to regions, countries, and cities. This report takes the broader definition and considers, therefore, a city as a part of the global market. I allocate latent demand across areas of dominant influence based on the relative economic importance of cities within its home country, within its region, and across the world total. Not all cities are estimated within each country as demand may be allocated to adjacent areas of influence. Since some cities have higher economic wealth than others within the same country, a city’s population is not generally used to allocate latent demand. Rather, the level of economic activity of the city is used vis-à-vis others.

Read more and order at The 2018-2023 World Outlook for Umbilical Cord Blood Stem Cells

Europe Stem Cell Market Growth, Trends and Forecasts 2017 – 2022 – Biotechnology, Healthcare, Stem Cells Industries

The Europe Stem Cell Market Growth, Trends and Forecasts 2017 – 2022 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

The European stem cell market is one of the most rapidly growing markets. The market is currently valued at USD 4.2 billion and is expected to grow at a CAGR of 15.7% over a forecast period.

EuropeStem Cells Market- Market Dynamics

Stem cell research is one of the most exciting areas of science in the 21st century and has the potential to revolutionize the way we treat conditions, including degenerative diseases for which few effective treatments currently exist. Researchers, governments, and the general public have high expectations from this field and they hope that this research will one day produce great results that might cure diseases such as Parkinson's, Diabetes, Cancer and Alzheimer's.

Drivers

There are several factors driving the growth of the stem cells market in Europe. Some of these are:

Increased interest in patients willing to undergo the stem cell treatment

Increase in the approval for clinical trials in stem cell research

Recent developments such as the increase in the number of clinical trials in stem cell research

Developments in the field of human stem cells

Restraints

Although there is ample scope for growth in the stem cells market in Europe, there are factors restraining it as well. Some of them are:

Expensive treatment procedures

Regulatory complications

Ethical framework

The stem cell research market is segmented on the basis of service, therapeutic application, treatment, and geography. In the stem cell segmentation by service mode, stem cell banking occupies the majority share of the market. In stem cell segmentation by treatment mode, allogeneic stem cell therapy market occupies the majority share. On the basis of geography, the market has been segmented into the UK, Spain, Germany, France and Denmark.

Key Deliverables:

Market analysis for Europestem cells market, with region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions where this industry is blooming and to also identify the regions that are still untapped.

Read more and order at Europe Stem Cell Market Growth, Trends and Forecasts 2017 – 2022

Neural Stem Cell Assays – Biotechnology, Healthcare, Stem Cells Industries

The Neural Stem Cell Assays Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

Neural stem cells offer a valuable model system for delineating the cellular and developmental processes in normal and diseased states of the central nervous system. In particular, neural stem cells have huge potential in regenerative medicine, owing to their expansion capability in culture and the ability to differentiate into multiple sub–neural lineages.

Neural Stem Cell Assays provides a detailed and comprehensive review of the basic methods for neural stem cell cultures. Including an overview of progress in the field over the past decade, Neural Stem Cell Assays is a one–stop reference for consistent methods and reliable tools that span the entire assay work flow, from isolation or generation of neural stem cells to characterization, manipulation and final application of neural stem cells in disease paradigms such as Parkinson′s disease, multiple sclerosis and amyotrophic lateral sclerosis.

An excellent source of information for academic, pharmaceutical and biotechnology researchers who are new to the neural stem cell field, Neural Stem Cell Assays is an invaluable to experienced users who wish to integrate newly developed tools and technologies into their workflow. The book also covers important course material for students at the undergraduate and graduate level who are learning the basics of neural stem cell cultures, and differentiation to sub–neural lineages.

Read more and order at Neural Stem Cell Assays

Global Stem Cell Assay Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 – 2023 – Biotechnology, Healthcare, Stem Cells Industries

The Global Stem Cell Assay Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 – 2023 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

The global market of stem cell assay is anticipated to reach USD 1,367.3 Million by 2022 at a CAGR of 21.5% during 2016 to 2022. Due to Rising Investment in Research Related Activities, Funding for Stem Cell Research Technological Advancements. The global market of stem cell assay has been segmented on the basis of type of assay, detection, kit, instrument, end-user, application, and region. Major strategies adopted by key players are collaboration, product launch, partnership and acquisition and merger etc. The key players in the global market of stem cell assay are Promega Corporation (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Merck KGaA (Germany), Hemogenix Inc. (U.S.), Bio-Rad Laboratories, Inc (U.S.), STEMCELL Technologies Inc. (CA), Cellular Dynamics International, Inc. (U.S.) and Bio-Techne Corporation (U.S.).

Market growth can be recognized due to the increasing investment in research related activities, high prevalence of chronic diseases, and technological advancement. However, high cost of stem cell based therapies and stringent regulatory policies are key factors restraining the growth of this market.

The global market of stem cell assay has been segmented on the basis of type of, kit, detection, instrument assay, application, end-user, and region. On the basis of type of assay, the global market is segmented into viability/cytotoxicity, proliferation, differentiation, isolation & purification, cell identification, function and apoptosis. The viability/cytotoxicity segment is anticipated to be the major and fastest-growing segment of the global market in 2016; while, the isolation & purification segment is anticipated to grow at the highest CAGR during the coming period. The adult stem cell kits are again segmented into mesenchymal stem cell kits, hematopoietic stem cell kits, induced pluripotent stem cell kits (IPSCs), umbilical cord stem cell kits and neuronal stem cell kits. The adult stem cell kits segment is expected to witness the highest CAGR during 2016 to 2022. The huge growth in this segment can be chiefly attributed to the effectiveness of this type of kit in cell analysis.

Based on detection, the global market of stem cell assay has been segmented into detection and instruments kits. The instrument segment is estimated to witness the highest CAGR during 2016 to 2022. The huge growth in this segment is associated with the increasing demand for instrument from research and medical services.

On the basis of Geography, the stem cell assay market is segmented into Europe, North America, Asia pacific, and ROW. The market is dominated by North America, which is followed by Europe. Growth in the North American regions is chiefly driven by the increasing patient pool and rising incidence and prevalence of chronic diseases in North coming period. However, the RoW region is anticipated to witness the highest CAGR during the coming period. The huge growth in this segment is centered in the Middle East, Latin America, and Africa due to the rising adoption of stem cell based therapies in these region.

The key players in the global market of stem cell assay are Promega Corporation (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Merck KGaA (Germany), Hemogenix Inc. (U.S.), Bio-Rad Laboratories, Inc (U.S.), STEMCELL Technologies Inc. (CA), Cellular Dynamics International, Inc. (U.S.) and Bio-Techne Corporation (U.S.). Major strategies adopted by these key players are collaboration, product launch, partnership and acquisition and merger etc.


Note:
Please allow up to 72 hours for delivery.

Read more and order at Global Stem Cell Assay Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 – 2023

Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking Market – Biotechnology, Healthcare, Stem Cells Industries

The Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking Market Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Stem Cells Markets.

This market insight on the global cell banking market analyses disruptive technologies and provides details on game-changing companies. Biopharmaceutical companies are increasingly partnering with CMOs and CROs to store their proprietary cell lines and develop new ones. With increased collaborations, CMOs are coming up with niche and specific services for cell line development and cell banking.

They are focusing on providing gene to GMP services, thereby expanding their service portfolios. Mammalian cell culture technology is the highest-growing system across all other cell systems. With the increase in infectious diseases, the development of novel mammalian cell culture systems is expected to evolve. With the growing need for the proper storage of cultured cell banks, CMOs are developing long-term preservation techniques through continuous temperature monitoring. With the emergence of single-use technologies and new developments in cryopreservation technologies and upstream/downstream processes, the cell banking market is expected to experience robust growth, with the major share being captured by contractors as they specialise in new technologies. CMOs are turning towards emerging markets such as Asia-Pacific. However, issues with delivery, service, IP protection, and regulatory and product quality are curbing growth.

The key companies covered in the study include SGS Life Sciences, Charles River Laboratories, Wuxi AppTech, BioReliance Corporation, Eurofins, and Lonza.

Read more and order at Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking Market